Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Veeva Systems VEEV recently announced that UCB has selected Veeva Safety Suite to unify its global pharmacovigilance operations. Through the deployment, UCB will standardize safety processes on a single platform, enabling faster case processing, enhanced oversight and streamlined regulatory submissions while supporting greater automation across safety workflows.

The latest win underscores the growing adoption of Veeva’s safety and regulatory solutions among large biopharmaceutical companies. For investors, the agreement reinforces Veeva’s position as a leading life sciences cloud software provider and highlights the company’s ability to deepen customer relationships through its connected platform strategy, supporting long-term revenue growth opportunities.

Likely Trend of VEEV Stock Following the News

Shares of VEEV have traded flat since the announcement on Tuesday. In the year-to-date period, shares of the company have lost 27.7% compared with the industry’s 20% decline.  The S&P 500 increased 6.3% in the same time frame.

The UCB deal is expected to strengthen Veeva’s long-term growth prospects by expanding the adoption of its Safety Suite across a global biopharmaceutical organization. Beyond adding to Veeva’s recurring subscription revenue base, the deployment validates the company’s strategy of offering an integrated platform spanning safety, regulatory and quality functions. As more life sciences companies seek to automate pharmacovigilance processes and improve compliance, successful enterprise-scale implementations like UCB’s can support additional customer wins, higher platform penetration and durable revenue growth over time.

VEEV currently has a market capitalization of $26.75 billion.Zacks Investment Research

Image Source: Zacks Investment Research

More on the News

UCB is adopting Veeva Safety Suite as a unified platform for end-to-end pharmacovigilance operations. The suite includes Veeva Safety for the intake, processing and submission of adverse event cases, Veeva SafetyDocs for managing safety-related documents and workflows, Veeva Safety Workbench for advanced analytics and scalable reporting and Veeva Safety Signal for automated signal detection. UCB will also leverage the Veeva Safety-RIM Connection, which automatically shares product information across regulatory and safety functions, helping maintain consistent, trusted data while improving operational efficiency and compliance.

The implementation forms a key part of UCB’s broader safety transformation initiative. By consolidating global and local safety workflows onto a single platform, the company aims to accelerate case processing, strengthen oversight and support low-touch, automated operations.

Story Continues

Management noted that the strategic partnership with Veeva positions UCB to further expand automation capabilities across its safety organization. For Veeva, the deployment represents another validation of its connected applications strategy and highlights growing demand among large biopharma companies for integrated cloud-based safety and regulatory solutions.

Favorable Industry Prospect for VEEV

Per a report by Fortune Business Insights, the global life science software market size was valued at $17.69 billion in 2025 and is projected to grow to $43.19 billion by 2034, exhibiting a CAGR of 10.50%.

The global life sciences software market is growing due to increasing demand for cloud-based platforms that help pharmaceutical and biotechnology companies streamline regulatory compliance, drug development and safety monitoring. Rising adoption of AI and automation is further accelerating the shift from legacy systems to integrated software solutions.

A Recent Development by VEEV

Recently, Veeva exited the fiscal first quarter of 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.

Veeva continues to strengthen its position in life sciences software through rapid innovation in artificial intelligence and expanding customer adoption. During the first quarter, the company significantly advanced its industry-specific AI strategy. Ostro, acquired in March, is now delivering compliant conversational AI for more than 50 brands, while Vault AI remains on track for deployment across all Vault applications in August.

VEEV’s Zacks Rank & Key Picks

Currently, VEEV carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report

Globus Medical, Inc. (GMED) : Free Stock Analysis Report

Veeva Systems Inc. (VEEV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

HealthEquity, Inc. HQY has been gaining from its business model and strategy. The optimism, led by a solid first-quarter fiscal 2027 performance and strength in Health Savings Accounts (HSAs), is expected to contribute further. However, data security threats are major concerns.

In the year-to-date period, the Zacks Rank #3 (Hold) company’s shares have lost 2.9% compared with the 7.4% decline of the industry. The S&P 500 has increased 6.3% during the said time frame.

The renowned provider of technology-enabled services platforms for healthcare savings and spending decisions has a market capitalization of $7.5 billion. The company projects 15.2% growth over the next five years and expects to witness continued improvements in its business. HealthEquity’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 12.02%.Zacks Investment Research

Image Source: Zacks Investment Research

Reasons Favoring HQY’s Growth

AI & Digital Innovation Drive Scalable Efficiency:In the fiscal first quarter of 2027, management said AI-driven tools reduced manual handling of member and client service emails by 25%. In targeted workflows such as card servicing and claims inquiries, AI-enabled automation reduced manual efforts by more than 90% and accelerated processing times by up to 50%. These initiatives are being paired with continued technology and security investments embedded in the raised fiscal 2027 outlook, suggesting management intends to keep pushing automation while sustaining service quality.

Expansion of Health Savings Accounts: HealthEquity has experienced significant growth in its HSA offerings. As of April 30, 2026, the total number of HSAs for which HealthEquity served as a non-bank custodian was 10.6 million, up 8% year over year.

HealthEquity reported 909,000 HSAs with investments as of April 30, 2026, up 18% year over year. Total accounts, as of April 30, 2026, were 17.8 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs).

Total HSA assets were $37.1 billion at the end of April 30, 2026, up 19% year over year. This included $17.5 billion of HSA cash and $19.6 billion of HSA investments. This figure compares to our fiscal first-quarter HSA cash and HSA investments projection of $17.6 billion and $17.9 billion, respectively. We had projected total HSA assets of $35.5 billion for the fiscal first quarter.

Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $1.0 billion as of April 30, 2026.

Story Continues

Strong Q1 Results: HealthEquity exited first-quarter fiscal 2027 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Improvements in operating and gross margins also bode well.

HealthEquity management noted that the company opened approximately 172,000 new HSAs during the quarter. Management noted that the company outpaced industry HSA growth, supported by strong client retention, an active enterprise sales pipeline and continued adoption of HSA-qualified plans.

Management also emphasized that digital engagement continues to strengthen, with monthly active mobile usage surging 90% year over year. The increased use of the mobile platform is helping improve member engagement, boost investing activity and support marketplace adoption, all of which are expected to enhance long-term member lifetime value.

A Factor That May Offset HQY’s Gains

Data Security Threats: HealthEquity manages sensitive personal data and large custodial balances, which keeps cybersecurity risk elevated despite recent progress in fraud reduction. The company remains subject to a consolidated putative class action related to a fiscal 2025 cybersecurity incident involving a business partner’s user account and is also subject to regulatory inquiries connected to that incident.

In May 2026, the company filed a renewed motion to compel arbitration, and the potential loss associated with the lawsuit and any regulatory action was not reasonably estimable based on available information. Any adverse outcome could increase costs, create operational distraction and impact member and client confidence, which can weigh on the long-term margin and growth profile.

Estimate Trend

HealthEquity has been witnessing a positive estimate revision trend for fiscal 2027. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 9 cents north to $4.71.

The Zacks Consensus Estimate for second-quarter fiscal 2027 revenues is pegged at $349.6 million, implying a 7.3% rise from the year-ago reported number. The consensus mark for fiscal second-quarter EPS is pinned at $1.19, implying a 10.2% improvement year over year.

Key Picks

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted EPS of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report

Globus Medical, Inc. (GMED) : Free Stock Analysis Report

HealthEquity, Inc. (HQY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Senseonics SENS recently entered into a strategic partnership with Welldoc to develop a next-generation mobile application for its Eversense 365 continuous glucose monitoring (CGM) system. The new app is expected to enhance the user experience while supporting broader integration with leading digital health platforms.

From an investor's standpoint, the collaboration reflects Senseonics’ continued efforts to strengthen the Eversense ecosystem and improve the value proposition of its flagship CGM platform. The move could support customer adoption and retention over time while reinforcing the company’s competitive position in the rapidly evolving diabetes management market.

Likely Trend of SENS Stock Following the News

Shares of SENS have traded flat since the announcement in yesterday’s trading. In the year-to-date period, shares of the company have gained 31.6% against the industry’s 19.9% decline.  The S&P 500 increased 6.4% in the same time frame.

The partnership is expected to strengthen Senseonics’ long-term growth prospects by enhancing the overall Eversense 365 user experience and expanding its connectivity within the digital health ecosystem. Improved interoperability with widely used health platforms and the potential addition of AI-driven features could make the product more attractive to both patients and healthcare providers. Over time, these enhancements may support higher adoption, improve customer retention and help differentiate Eversense 365 in the competitive CGM market, thereby creating a stronger foundation for recurring revenue growth.

SENS currently has a market capitalization of $310.6 billion.Zacks Investment Research

Image Source: Zacks Investment Research

More on the News

Under the partnership, Senseonics and Welldoc will develop a customized mobile application for Eversense 365, the world’s first and only one-year CGM system. The next-generation app will retain all current functionalities while introducing enhancements designed to improve usability and patient engagement. A key feature of the upgrade is seamless integration with Apple Health and Google Health Connect, enabling users to consolidate glucose, fitness and broader health data within a single platform. The app will also continue to support integration with the twiist Automated Insulin Delivery (AID) system, where available, extending the functionality of the Eversense ecosystem.

The new application is expected to feature a redesigned interface with improved workflows and visual components across sensor and transmitter setup, pairing, activation, synchronization, communication status monitoring, data displays and alerts. The U.S. launch is targeted for the second half of 2026, followed by availability in Europe in early 2027.

Story Continues

Beyond the initial rollout, the companies plan to collaborate on future software releases, leveraging Welldoc’s AI-powered digital health platform. Potential enhancements include CGM-informed bolus calculations, medication management tools, metabolic tracking capabilities, digital logbooks and educational resources, which could further expand the clinical utility and appeal of the Eversense platform over time.

Favorable Industry Prospect for SENS

Per a report by Future Market Insights, the CGM device market is projected to grow from $12.7 billion in 2025 to $54.6 billion by 2035, at a CAGR of 15.7%.

Adoption has been driven by growing clinical evidence demonstrating improved outcomes through real-time glucose monitoring and trend analysis.

A Recent Development by SENS

Senseonics recently presented new real-world evidence at the American Diabetes Association 2026 Scientific Sessions, highlighting the strong performance of its Eversense 365 CGM system. The analysis, which included data from 12,360 Eversense 365 sensors in open-loop users and 153 closed-loop users utilizing the twiist AID system, demonstrated sustained accuracy, favorable glucometrics and positive patient outcomes over a full year. The findings build on data previously presented at ATTD 2026 and further validate the differentiated value proposition of Eversense 365, the first and only one-year CGM system.

SENS’s Zacks Rank & Key Picks

Currently, SENS carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report

Globus Medical, Inc. (GMED) : Free Stock Analysis Report

Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

10x Genomics TXG recently announced the acquisition of Proteintech Genomics, a division within Proteintech Group that develops high-plex proteomic solutions for single-cell and spatial biology applications. The move expands TXG's capabilities in proteomics and supports its broader strategy of advancing multiomics research through integrated RNA and protein analysis.

Proteintech Genomics brings technologies, including the Human Discovery Panel, an antibody-based single-cell protein panel compatible with 10x Genomics' Flex chemistry workflows. Management believes the acquisition will strengthen its single-cell and spatial biology platforms, while the company expects the transaction to have no meaningful impact on its near-term financial outlook.

Likely Trend of TXG Stock Following the News

Shares of TXG have gained 4.8% since the announcement in yesterday's trading. In the year-to-date period, shares of the company have gained 87.6% against the industry's 20.5% decline.  The S&P 500 increased 8.4% in the same time frame.

The acquisition is expected to strengthen TXG's long-term growth prospects by expanding its presence in the rapidly evolving proteomics market and enhancing its multiomics capabilities. By integrating Proteintech Genomics' protein-analysis technologies with its existing single-cell and spatial platforms, TXG can offer researchers a more comprehensive view of cellular biology through combined RNA and protein measurements. The deal also has the potential to increase customer adoption, drive higher consumables usage and improve platform stickiness, while positioning the company to capitalize on emerging opportunities in AI-driven biological modeling and next-generation life sciences research.

TXG currently has a market capitalization of $3.7 billion.Zacks Investment Research

Image Source: Zacks Investment Research

More on the News

The acquisition significantly broadens 10x Genomics' proteomics portfolio by adding Proteintech Genomics' differentiated technologies, including the Human Discovery Panel, which the company describes as the largest antibody-based single-cell protein panel.

The panel is designed to support integrated analysis of intracellular proteins, cell-surface proteins and transcriptomic profiles within sequencing-compatible workflows. Importantly, the technology is already compatible with 10x Genomics' Flex chemistry, including the Flex Apex assay, enabling researchers to combine RNA and protein measurements within a unified workflow. Management believes that integrating transcriptomic and proteomic information at the single-cell and spatial levels will play an increasingly important role in advancing biological research and discovery.

Story Continues

The transaction also aligns with 10x Genomics' broader strategy of enabling multimodal biological analysis across its single-cell and spatial platforms. Proteintech Genomics' protein panels were purpose-built for 10x workflows and are already being used by researchers to simultaneously analyze RNA and protein expression. By bringing these capabilities in-house, TXG aims to simplify workflows that currently require multiple vendors and technologies to harmonize RNA and protein data.

The company also sees opportunities to extend these protein-analysis capabilities to its recently launched Atera platform. Researchers across fields such as immunology, oncology, neuroscience and cell biology are increasingly adopting combined transcriptomic and proteomic approaches to gain deeper insights into cellular identity, function and disease mechanisms, making the acquisition a strategic addition to TXG's long-term innovation roadmap.

Favorable Industry Prospect for TXG

Per a report by Grand View Research, the global proteomics market size was valued at $38.4 billion in 2025 and is projected to grow beyond $97.7 billion by 2033, at a CAGR of 13.3%.

The market is witnessing significant growth driven by the rising prevalence of chronic and infectious diseases, growing preference for personalized medicine and the increasing demand for rapid & advanced diagnostic solutions in target disease treatment.

Recent Developments by TXG

Recently, 10x Genomics exited the first quarter of 2026 on a solid note, with both earnings and revenues surpassing the Zacks Consensus Estimate. While total revenues declined year over year due to the absence of prior-year one-time license and royalty revenues, underlying business performance remained healthy, driven by higher consumables demand, increased services revenues, growth across the EMEA and Asia-Pacific regions, expanding gross margin and disciplined cost management.

The company also significantly narrowed its operating loss year over year. During the quarter, TXG strengthened its innovation pipeline with the launch of Atera, a next-generation spatial whole-transcriptome platform that offers single-cell sensitivity at scale and is expected to support growth following its planned commercialization in the second half of 2026.

TXG's Zacks Rank & Key Picks

Currently, TXG carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today's Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry's 12.6% growth. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry's 9.5% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry's 12.6% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report

Globus Medical, Inc. (GMED) : Free Stock Analysis Report

10x Genomics (TXG) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.

This Zacks Rank #2 (Buy) company's shares have lost 24.9% in the year-to-date period compared with the 20.6% decline of the industry. The S&P 500 Composite has increased 8.3% during the said time frame.

The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $27.32 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.5%.Zacks Investment Research

Image Source: Zacks Investment Research

Reasons Favoring VEEV's Growth

Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continues to build as large customers move off legacy CRM deployments and standardize commercial workflows. Management highlighted recent global selections from Teva and Merck KGaA and noted that Veeva has secured 10 wins versus six for Salesforce, within its defined top 20 cohort, with four decisions still pending.

The company also cited an overall Vault CRM win rate above 80% and more than 150 customers live on Vault CRM, supported by over 40 completed migrations. This installed base creates a multi-year services and subscription runway and should support the attachment of adjacent commercial applications.

Diversified Platform Driving Durable Growth:Veeva Systems' long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems' Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.

Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.

Story Continues

Strong Q1 Results: Veeva Systems exited the fiscal first quarter of 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others' revenues also bodes well.

Veeva Systems continues to strengthen its position in life sciences software through rapid innovation in artificial intelligence and expanding customer adoption. During the first quarter, the company significantly advanced its industry-specific AI strategy. Ostro, acquired in March, is now delivering compliant conversational AI for more than 50 brands, while Vault AI remains on track for deployment across all Vault applications in August.

A Factor That May Offset VEEV's Gains

Market Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.

Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.

Estimate Trend

Veeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $8.87.

The Zacks Consensus Estimate for second-quarter fiscal 2027 revenues is pegged at $904.1 million, indicating a 14.6% improvement from the year-ago quarter's reported number. The EPS estimate for the second quarter of fiscal 2027 is pinned at $2.19, implying a 10.1% improvement year over year.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today's Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry's 12.6% growth. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry's 9.5% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry's 12.6% growth. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report

Globus Medical, Inc. (GMED) : Free Stock Analysis Report

Veeva Systems Inc. (VEEV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Zukunftsmärkte haben sich nach dem Wochenende wieder erholt. Der Dow Jones Industrial Average schloss bei 50.786 Punkten, was einem Rückgang von 0,17 % entspricht. Der S&P 500 schloss bei 7.405 Punkten, was einem Anstieg von 0,30 % entspricht. Der Nasdaq schloss bei 25.929 Punkten, was einem Anstieg von 0,87 % entspricht. Cleveland-Cliffs (NYSE: CLF) wurde von Sidoti auf 'Halt' erhoben, ohne Zielpreis. FuelCell Energy (NASDAQ: FCEL) wurde von Canaccord auf 'Kauf' erhöht, wobei der Preisziel auf 30 $ erhöht wurde.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Cooper Companies, Inc. hat im zweiten Quartal des Geschäftsjahres 2026 einen bereinigten Gewinn pro Aktie (EPS) von 1,21 US-Dollar erzielt, was einem Anstieg um 26,0 % gegenüber dem Vorjahreszeitraum entspricht und die Zacks-Konsensschätzung von 1,10 US-Dollar um 10,0 % übertraf. Die operativen Verbesserungen haben den Gewinnwachstum getrieben.

Die GAAP-Verlust pro Aktie für das Quartal betrug 40 Cent, was erheblich niedriger war als der GAAP-EPS des Vorjahreszeitraums von 44 Cent, der durch eine litigationsbezogene Belastung beeinflusst wurde, die mit der Beilegung von Ansprüchen verbunden ist, die im Dezember 2023 aufgrund eines freiwilligen Produktrückrufs bei CooperSurgical entstanden sind.

Die Einnahmen des COO beliefen sich im zweiten Quartal auf 1,08 Milliarden US-Dollar und stiegen um 8 % gegenüber dem Vorjahreszeitraum. Die Figur übertraf die Zacks-Konsensschätzung von 1,05 Milliarden US-Dollar um 2,6 %.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Fresenius Medical Care AG & Co. KGaA hat kürzlich die globale Einführung der digitalen Plattform kinexus angekündigt, um Heimdialyseprogramme zu unterstützen und eine vernetzte, patientenorientierte Pflege zu fördern. Die Plattform integriert Fernbehandlungsüberwachung, Rezeptmanagement und operative Workflows für beide peritoneale Dialyse (PD) und Heimhemodialyse (HHD) innerhalb eines Systems.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

GE HealthCare hat kürzlich bekannt gegeben, dass die FDA der MIM Contour ProtegeAI+ 2.0, einer AI-gesteuerten Auto-Konturierungssoftware zur Unterstützung von Strahlentherapieplanungen, den Zulassungsstatus 510(k) gewährt hat. Die neueste Version erweitert die klinischen Fähigkeiten mit neuen Magnetresonanz-Brain- und aktualisierten Computertomographie-Male-Pelvis-Modellen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

DexCom, Inc. DXCM ist gut positioniert für Wachstum in den kommenden Quartalen, unterstützt durch das erhebliche Potenzial des kontinuierlichen Glukose-Monitorings (CGM)-Marktes. Ein starkes Ergebnis im ersten Quartal 2026 und eine starke internationale Präsenz werden weitere Beiträge leisten. Risiken bleiben hinsichtlich starker Konkurrenz bestehen.